Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis

A New Preparation Method for Ophthalmic Drug Nanoparticles

“…On the other hand, it has been reported that the capability of drugs to penetrate across the cornea can be significantly improved by decreasing the particle size using nanoparticles [3,9,[13][14][15]. Ophthalmic formulations containing drug nanoparticles present a possible solution to the limitations surrounding ocular drug penetration [16][17][18][19], and it is known that decreasing direct cellular stimulation and reducing the amount drug used by increasing its bioavailability are useful ways to circumvent the side effects related to drug delivery [6]. It is expected that ophthalmic drug systems using nanoparticles may provide an alternative strategy for increasing ocular drug penetration [16][17][18][19].…”

“…Ophthalmic formulations containing drug nanoparticles present a possible solution to the limitations surrounding ocular drug penetration [16][17][18][19], and it is known that decreasing direct cellular stimulation and reducing the amount drug used by increasing its bioavailability are useful ways to circumvent the side effects related to drug delivery [6]. It is expected that ophthalmic drug systems using nanoparticles may provide an alternative strategy for increasing ocular drug penetration [16][17][18][19]. This review addresses the usefulness of ophthalmic formulations containing drug nanoparticles.…”

Development and characterization of PLGA nanoparticles as delivery systems of a prodrug of zidovudine obtained by its conjugation with ursodeoxycholic acid

“…PLGA is biocompatible and it is eliminated from the body through natural pathways, being degraded to the lactic and glycolic acids (Jalil, 1990;Johansen et al 2000;Bala et al, 2004). In the field of biomedical applications, the submicron size of the nanoparticles (NPs) can allow their administration by a variety of routes, such as intravenous, oral, nasal, ocular and transdermal (Chen et al, 2012;Danhier et al, 2012;Tomoda et al, 2012). However, NPs can have some limitations due to their small size and large surface area that can limit drug loading and cause relative high burst release (Leo et al, 2006b;Nafee et al, 2009).…”

Effect of Solid Nanoparticle of Indomethacin on Therapy for Rheumatoid Arthritis in Adjuvant-Induced Arthritis Rat

“…It is expected that drug systems using nanoparticles may provide an alternative strategy for increasing drug bioavailability. [19][20][21][22] On the other hand, we have also developed methods to prepare tranilast solid nanoparticles by a bead mill method, and showed that these solid nanoparticles enhance drug bioavailability. 23,24) It is possible that decreasing the amount of orally administered NSAIDs by improving their bioavailability may lead to an expansion of their usage as therapy for RA patients.…”

“…[16][17][18] Implants fabricated using the biodegradable polymer PLGA [poly(DL-lactide-co-glycolide)] with mean particle diameters of 50-200 nm have been widely utilized as carriers for bioactive molecules and present a possible solution to limitations surrounding ocular drug penetration. [19][20][21][22] In addition, Sha et al 18) developed a newly designed oral nanotherapeutic using redox nanoparticles (RNP O ) with the potential to scavenge reactive oxygen species including nitroxide radicals for the treatment of inflammation in the gastrointestinal tract. RNP O is a core-shell-type polymeric micelle prepared by the self-assembly of methoxy-poly(ethylene glycol)-b-poly[4-(2,2,6,6-tetramethylpiperidine-1-oxyl) oxymethyl-styrene].…”